NCT06525272View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pleurisy
Interventions
DRUG

Recombinant Human Chymotrypsin(OsrhCT)

Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.

DRUG

Placebo for Recombinant Human Chymotrypsin(OsrhCT)

Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.

Trial Locations (4)

230031

Anhui Chest Hospital, Hefei

410004

Changsha Central Hospital, Changsha

430000

Wuhan Pulmonary Hospital, Wuhan

518112

Shenzhen Third People's Hospital, Shenzhen

Sponsors
All Listed Sponsors
lead

Healthgen Biotechnology Corp.

INDUSTRY

NCT06525272 - A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy | Biotech Hunter | Biotech Hunter